Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
Metformin Chemoprevention of Oral Premalignant Lesions
Sponsor: Thomas Jefferson University
Terminated
Slow accrual
Other terminated trials from Thomas Jefferson University
Listed as NCT05536037, this PHASE1 trial focuses on Erythroplakia and Leukoplakia and remains terminated or withdrawn. Sponsored by Thomas Jefferson University, it has been updated 8 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE1
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thomas Jefferson University
For direct contact, visit the study record on ClinicalTrials.gov .